[{"indications": "Indications\u00a0\n(From 6.1.2.3 Other antidiabetic drugs: British National Formulary)\n6.1.2.3 Other antidiabetic drugs", "name": "LIRAGLUTIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.3 Other antidiabetic drugs"], "cautions": "Cautions\u00a0discontinue if symptoms of acute pancreatitis\r\n(persistent, severe abdominal pain); interactions: Appendix 1 (antidiabetics)", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances including nausea,\r\nvomiting, constipation, diarrhoea, dyspepsia, abdominal pain and distension,\r\nflatulence, gastritis, gastro-oesophageal reflux disease, decreased\r\nappetite; headache, dizziness, fatigue; fever, bronchitis, nasopharyngitis;\r\nhypoglycaemia; injection site reactions; also reported acute pancreatitis, thyroid neoplasm, goitre, increased blood calcitonin,\r\nangioedema", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/203878.htm", "doses": ["By subcutaneous injection, adult over 18 years, initially 0.6\u00a0mg once daily,\r\nincreased after at least 1 week to 1.2\u00a0mg once daily, further increased\r\nif necessary after an interval of at least 1 week to max. 1.8\u00a0mg once\r\ndaily", "Dose of concomitant sulfonylurea may need\r\nto be reduced"], "pregnancy": "Pregnancy\u00a0avoid\u2014toxicity in animal studies"}]